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Abstract
Amyloid β is an in vitro substrate for P-glycoprotein (P-gp), an efflux pump at the blood brain barrier
(BBB). The Multi Drug Resistance (ABCB1) gene, encoding for P-gp, is highly polymorphic and this
may result in a changed function of P-gp and may possibly interfere with the pathogenesis of
Alzheimer's disease. This study investigates to what extent ABCB1  Single Nucleotide
Polymorphisms (SNPs; C1236T in exon 12, G2677T/A in exon 21 and C3435T in exon 26) and
inferred haplotypes exist in an elderly population and if these SNPs and haplotypes differ between
patients with dementia and age-matched non-demented control patients. ABCB1 genotype, allele
and haplotype frequencies were neither significantly different between patients with dementia and
age-matched controls, nor between subgroups of different types of dementia nor age-matched
controls. This study shows ABCB1 genotype frequencies to be comparable with described younger
populations. To our knowledge this is the first study on ABCB1 genotypes in dementia. ABCB1
genotypes are presently not useful as a biomarker for dementia, as they were not significantly
different between demented patients and age-matched control subjects.
Findings
P-glycoprotein (P-gp), a 170 kDa membrane bound efflux
pump at the apical membrane of endothelial cells, func-
tions as part of the blood brain barrier (BBB) [1,2] and is
also expressed at the blood-cerebrospinal fluid (BCSF)
barrier, formed by the choroid plexus [3]. The Multi Drug
Resistance gene (ABCB1) encodes for P-gp. It is known
that the ABCB1 gene is highly polymorphic [4]. The three
most frequently occurring Single Nucleotide Polymor-
phisms (SNPs) are C1236T in exon 12 (dbSNP:
rs1128503), G2677T/A in exon 21 (dbSNP: rs2032582)
and C3435T in exon 26 (dbSNP: rs1045642) [5]. ABCB1
haplotypes composed of different SNPs may better repre-
sent changes in P-gp function [4].
The "amyloid hypothesis" states that accumulation of
beta amyloid peptides in the brain is the key event in the
pathogenesis of Alzheimer's Disease (AD) [6]. Amyloid
deposits in plaques in brain parenchyma and along the
vascular system [7]. Amyloid β is an in vitro substrate for
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P-gp [8] and recent research found that P-gp deficiency at
the BBB increases β amyloid deposition in an AD mouse
model [9]. Vogelgesang et al.[10] showed P-gp expression
at the BBB to be inversely correlated to the number of
amyloid plaques in the medial temporal lobe in 243 non-
demented elderly. Thus, the efflux pump P-gp possibly
plays a role in the pathogenesis of late-onset dementia by
interfering with the amyloid clearance, as late-onset AD
would result from inefficient clearance of beta amyloid
from the brain [11].
We hypothesized ABCB1  genotypes to be related to
dementia occurrence as amyloid load in the brain is pos-
sibly inversely related to P-gp expression at the BBB and
ABCB1  SNPs and haplotypes may be related to P-gp
expression and function. This study aimed to test this
hypothesis in an elderly population consisting of patients
suffering from dementia and age-matched non-demented
control patients.
This prospective study was carried out at the geriatric diag-
nostic day-clinic of the Slotervaart Hospital, a teaching
hospital in Amsterdam, the Netherlands. Dementia was
diagnosed or excluded after performing complete geriatric
assessment including: Mini Mental State Examination
(MMSE) [12], the 7-Minute Neurocognitive Screening
Test[13] and laboratory testing, including thyroid func-
tion, levels of folic acid, thiamine and vitamin B12. There-
after, patients underwent more extensive
neuropsychological assessment and, if necessary, compu-
terized tomography or magnetic resonance imaging was
performed. Mild Cognitive Impairment (MCI) and differ-
ent types of dementia were diagnosed according to the
current guidelines [14-19]. We categorized patients as
unspecified dementia if the underlying process could not
be diagnosed. Age-matched controls were recruited from
the same diagnostic day-clinic. These participants did not
show any cognitive impairment. Most of these geriatric
patients were presented at the day clinic for a somatic
screening. The study protocol was approved by the Insti-
tutional Review Board of the Slotervaart Hospital, Amster-
dam, The Netherlands. Written informed consent was
obtained from each participant in this study.
From each participant a 2 ml EDTA blood sample was
obtained by venous puncture and genomic DNA was
extracted using the Qiagen QIAamp® DNA Mini Kit (Qia-
gen, Leusden, The Netherlands) according to the manu-
facturer protocol. ABCB1  was screened for C1236T in
exon 12 (dbSNP: rs1128503), G2677T/A in exon 21
(dbSNP: rs2032582) and C3435T in exon 26 (dbSNP:
rs1045642) by sequencing, as earlier described [20].
APOE genotype was determined using real-time polymer-
ase chain reactions based upon Koch et al. [21].
The Chi square statistic test was used to calculate whether
the alleles are in Hardy-Weinberg Equilibrium (HWE).
Linkage disequilibrium (LD) between ABCB1 SNPs was
performed by Graphical Overview of Linkage Disequilib-
rium (GOLD) software V1.1.0.0 [22] and haplotype anal-
ysis with the software package HPlus65v2.1.1 [23]. The
Pearson Chi-square test was used to compare categorical
variables and a one-way ANOVA for continuous variables.
Kruskal-Wallis testing was performed to compare educa-
tion level, scored on a seven-point scale, ranging from less
than 6 years of elementary school (score 1) to a university
degree (score 7) [24]. Logistic regression was performed to
investigate the role of the APOE ε4 allele as a possible con-
founder, with the different types of dementia compared to
controls as dependent variables and the described ABCB1
SNPs (as wild-type, heterozygous and homozygous
mutants) and APOE (as ε4 allele carriers vs. non-carriers)
as independent variables. A p-value of 0.05 or less was
considered statistically significant. Bonferroni corrections
were made in case of multiple testing. Statistical calcula-
tions were performed with SPSS for Windows (version
12.0, SPSS Inc., Chicago, IL, USA). A power analysis, using
NQUERY advisor version 5.0, was performed for Chi-
square testing between two groups (AD vs. controls) com-
paring proportions in three categories (wild-type, hetero-
zygous and homozygous mutants).
In total, 161 patients signed informed consent. Seven
patients were excluded, because of refusing further medi-
cal examination (n = 3) or because patients were diag-
nosed delirious (n = 4). The 154 included participants
consisted of 113 patients (48 AD, 19 Vascular Dementia
(VaD), 26 other dementia (OD), and 20 MCI) and 41 age-
matched controls. The group of OD included 10 patients
with a mixed type of dementia, 3 with Lewy Body Disease,
3 with alcohol induced dementia, 2 with Frontotemporal
Dementia and 8 "unspecified" dementia syndromes.
Baseline characteristics are presented in the table. The
total population (n = 154) had a mean age of 81.7 ± 5.9
(63.3–94.8) years and almost 60% was female. Age, gen-
der and education level were not significantly different
between the subgroups. Mean MMSE score was signifi-
cantly different between the dementia subgroups and the
control group (p < 0.001), which is as expected.
Only in the MCI group allele frequencies for G2677T/A
did not apply to Hardy Weinberg Equilibrium, although
the other allele frequencies in all other groups did apply
to HWE (results not shown). Strong linkage was observed
between C1236T and G2677T/A (ρ2  = 0.831, p <
0.000001), between C1236T and C3435T (ρ2 = 0.424, p <
0.000001) and between G2677T/A and C3435T (ρ2 =
0.456, p < 0.000001). In the table the ABCB1 genotype,
allele and haplotype frequencies are presented. Haplotype
data were inferred from genotype data only for CaucasianM
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Table 1: Demographic characteristics and ABCB1 genotype, allele and haplotype frequencies (n, (%))
Total POP (n = 154) Controls (n = 41) AD (n = 48) VaD (n = 19) OD (n = 26) MCI (n = 20)
Age, Mean ± SD (range) 81.7 ± 5.9 (63.3–94.8) 81.9 ± 5.7 (69.5–94.5) 81.0 ± 5.5 (71.9–93.3) 83.6 ± 5.6 (67.6–89.7) 82.1 ± 5.2 (69.6–94.8) 80.5 ± 6.9 (63.3–90.7)
Gender, n (%) female 92 (59.7) 27 (65.9) 33 (68.8) 8 (42.1) 11 (42.3) 13 (65.0)
Education, median IQR (range) 4 IQR: 3 (1–7) 4 IQR:3 (1–6)* 4 IQR:3 (1–7)† 5 IQR:2 (4–6)† 4 IQR: 3 (2–7)† 4 IQR:3 (2–6)*
Baseline MMSE, Mean ± SD (range) 21.2 ± 5.7 (3–30) 26.6 ± 2.2 (21–29)¶ 18.2 ± 4.4†,§ (6–26)# 18.1 ± 7.5†,§ (3–29) 20.9 ± 5.2† (12–30)† 25.3 ± 2.7 (19–30)†
Ethnicity, n (%) CAU 151 (98.1) 40 (97.6) 48 (100) 19 (100) 25 (96.2) 19 (95.0)
SNP C1236T (12)
CC 44 (28.6) 12 (29.3) 12 (25.0) 3 (15.8) 7 (26.9) 10 (50.0)
CT 75 (48.7) 20 (48.8) 25 (52.1) 10 (52.6) 14 (53.8) 6 (30.0)
TT 35 (22.7) 9 (22.0) 11 (22.9) 6 (31.6) 5 (19.2) 4 (20.0)
Allele freq T (%) 0.471 0.463 0.490 0.579 0.462 0.350
SNP G2677T/A (21)
GG 46 (29.9) 12 (29.3) 13 (27.1) 4 (21.2) 7 (26.9) 10 (50.0)
GT 67 (43.5) 16 (39.0) 24 (50.0) 9 (47.4) 13 (50.0) 5 (25.0)
TA 3 (1.9) 2 (4.9) 0 (0.0) 0 (0.0) 1 (3.8) 0 (0.0)
TT 38 (24.7) 11 (26.8) 11 (22.9) 6 (31.6) 5 (19.2) 5 (25.0)
Allele freq T (%) 0.474 0.488 0.479 0.553 0.462 0.375
Allele freq A (%) 0.010 0.024 0.000 0.000 0.019 0.000
SNP C3435T (26)
CC 32 (20.8) 9 (22.0) 5 (10.4) 2 (10.5) 8 (30.8) 8 (40.0)
CT 70 (45.5) 18 (43.9) 26 (54.2) 9 (47.4) 10 (38.5) 7 (35.0)
TT 52 (33.8) 14 (34.1) 17 (35.4) 8 (42.1) 8 (30.8) 5 (25.0)
Allele freq T (%) 0.565 0.561 0.625 0.658 0.500 0.425
Haplotype Total POPa (n = 148) Controls (n = 38) AD (n = 48) VaD (n = 19) OD (n = 24) MCI (n = 19)
T-T-T 130 (0.439) 33 (0.434) 43 (0.448) 20 (0.526) 22 (0.458) 12 (0.316)
C-G-C 114 (0.385) 29 (0.382) 34 (0.354) 11(0.289) 21 (0.438) 19 (0.500)
C-G-T 38 (0.128) 10 (0.132) 15 (0.156) 5 (0.132) 4 (0.083) 4 (0.105)
C-T-T 5 (0.017) 3 (0.039) 1 (0.010) 0 (0.000) 0 (0.000) 1 (0.026)
T - G - C 4  ( 0 . 0 1 4 )1  ( 0 . 0 1 3 )2  ( 0 . 0 2 1 ) 1 (0.026) 0 (0.000) 0 (0.000)
T-T-C 5 (0.017) 0 (0.000) 1 (0.001) 1 (0.026) 1 (0.021) 2 (0.053)
* missing for 2 patients. † missing for 1 patient. ‡p < 0.001 vs. controls. §p < 0.001 vs. MCI ¶performed in 22 controls. #missing for 3 patients.
Haplotype of the different SNPs, i.e. number of alleles and frequencies of the haplotype mentioned. C1236T-G2677T-C3435T;a 3 patients with an ethnicity different from Caucasian and 3 patients bearing an 
A allele at the 2677 (exon 21) position were excluded from haplotype analysis. POP = Population, AD = Alzheimer's Disease, VaD = Vascular Dementia, OD = Other dementias, MCI = Mild Cognitive 
Impairment, SD = Standard Deviation, IQR = Inter Quartile Range, MMSE = Mini Mental State Examination, CAU = Caucasian race, SNP = Single Nucleotide Polymorphism.Molecular Neurodegeneration 2006, 1:13 http://www.molecularneurodegeneration.com/content/1/1/13
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participants not possessing an A allele at position
G2677T/A in exon 21. No statistical differences were
observed for genotype data, allele frequencies and haplo-
type data between patients with dementia and age-
matched controls, nor between patients with different
types of dementia and age-matched controls. The logistic
regression analyses did not show the APOE ε4 allele as
confounder for the ABCB1 genotypes as possible risk fac-
tors for dementia (results not shown).
Frequencies of ABCB1  genotypes of the SNPs C1236T,
G2677T/A, C3435T in this elderly population are compa-
rable to earlier reports on younger populations
[20,25,26]. We did not find a relation between ABCB1
SNPs and different types of dementia. Whether ABCB1
SNPs and haplotypes result in different function of P-gp at
the BBB is not clear. In a study in 10 healthy volunteers
who were homozygous for the TTT haplotype and in 10
healthy volunteers who where homozygous for the CGC
haplotype, no differences in 11C-verapamil kinetics, as
measured by Positron Emission Tomography, were appar-
ent [27]. This could point out that ABCB1 SNPs and/or
haplotypes are not related to P-gp function at the BBB.
This first study on ABCB1 genotypes in dementia has 27%
power to detect differences in C3435T genotypes between
AD and control patients. Based upon our preliminary
results, 173 patients should be included in both the AD
and the control group to obtain an ideally 80% power.
This study and possible future ones may be combined in
a meta-analysis to achieve more power to detect differ-
ences in ABCB1 genotypes between the different groups.
In conclusion, our study suggests that frequencies of
ABCB1 genotypes and haplotypes are not significantly dif-
ferent between demented patients and age-matched con-
trol subjects and are presently not useful as biomarker for
(different types of) dementia.
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